Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3

An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring. Halozyme (NASDAQ: HALO) announced Monday that its drug, PEGPH20, did not meet a Phase 3 study?s main goal of improving how [?]